查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600897

移植HLA型檢測市場：依產品與服務、技術、移植類型、應用、最終用戶 - 2025-2030 年全球預測

HLA Typing for Transplant Market by Product & Service, Technology, Transplant Type, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，可移植HLA型檢測市值為9.9831億美元，預計到2024年將達到10.8639億美元，複合年成長率為9.09%，預計到2030年將達到18.3658億美元。

移植的HLA型檢測是一項重要的醫療實踐，可將器官或組織供體的人類白血球抗原 (HLA) 與受體的相匹配，確保相容性並降低排斥風險。這個過程對於腎臟、肝臟、心臟和骨髓移植等器官移植至關重要，其中準確的匹配極大地影響移植的成功和壽命。 HLA型檢測市場主要是由全球器官衰竭發生率上升和器官移植需求增加所推動的。此外，技術進步，特別是分子診斷技術的進步，提高了HLA型檢測的準確性和效率，促進了HLA型檢測在醫院和實驗室的應用。關鍵的成長要素包括器官捐贈意識的提高、政府支持移植活動的舉措的增加以及導致器官衰竭的慢性疾病盛行率的增加。然而， HLA型檢測成本高、器官可用性有限以及器官移植的倫理問題等挑戰正在限制市場成長。然而，這個領域充滿了機遇，特別是隨著次世代定序的進步和個人化醫療的傳播。在自動化HLA型檢測技術和高通量HLA型檢測技術等領域進行創新的公司可能具有競爭優勢。醫療保健基礎設施迅速改善的新興市場的擴張也為市場參與企業提供了利潤豐厚的機會。儘管有這些潛在的好處，嚴格的法律規範和匹配流程的複雜性仍然是主要障礙。未來的研究預計將集中於最佳化具有成本效益的技術並加速 HLA 匹配，以提高可及性和效率。該市場的特點是對創新和技術進步的持續需求，這表明投資於研發並採用數位醫療解決方案的主要企業可能會獲得市場佔有率。

主要市場統計
基準年[2023] 99831萬美元
預測年份 [2024] 1,086,390,000 美元
預測年份 [2030] 1,836.58 百萬美元
複合年成長率（%） 9.09%

市場動態：快速發展的移植HLA型檢測市場的關鍵市場洞察

可移植HLA型檢測市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 骨髓、器官和血液移植過程的發生率增加
    • 在個人化醫療中採用HLA型檢測以減少移植物排斥
  • 市場限制因素
    • 報銷不足和保險政策不足
  • 市場機會
    • 移植診斷和HLA型檢測方法領域的技術進步
    • 偏好免疫抑制治療以補充HLA型檢測
  • 市場挑戰
    • 對HLA型檢測不準確的擔憂

波特五力：駕馭移植HLA型檢測市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解移植HLA型檢測市場的外部影響

外部宏觀環境因素在塑造可移植HLA型檢測市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解移植HLA型檢測市場的競爭狀況

移植HLA型檢測市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣植入HLA型檢測市場供應商績效評估

FPNV定位矩陣是評估可移植HLA型檢測市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 骨髓、器官和血液移植手術的發生率上升
      • 在個人化醫療中採用HLA型檢測來減少移植物排斥
    • 抑制因素
      • 缺乏承保範圍和保險不足
    • 機會
      • 移植診斷和HLA型檢測方法領域的技術進步
      • 優先考慮免疫抑制治療以補充HLA型檢測
    • 任務
      • 對HLA型檢測不準確的擔憂
  • 市場區隔分析
    • 技術：採用分子檢測技術，特異性高、重現性佳
    • 產品和服務：優先考慮促進資料解釋和實驗室工作流程管理的軟體和服務
    • 移植類型：越來越多使用幹細胞移植療法來治療白血病、淋巴瘤、骨髓瘤和免疫系統疾病
    • 應用： HLA型檢測在器官移植的診斷應用的應用
    • 最終用戶：高度滲透到獨立參考實驗室，以實現高通量能力和擴充性。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章移植HLA型檢測市場：依產品及服務分類

  • 裝置
  • 試劑/耗材
  • 軟體和服務

第7章 移植HLA型檢測市場：依技術分類

  • 分子檢測技術
    • 基於PCR的分子檢測
      • 即時PCR
      • 序列特異性寡核苷酸PCR
      • 序列特異性引子PCR
    • 基於定序的分子測定
      • 次世代定序
      • 桑格序列
  • 非分子檢測技術

第8章 依移植類型分類的HLA型檢測市場

  • 器官移植
  • 幹細胞移植
  • 組織移植

第 9 章 移植HLA型檢測市場：依應用分類

  • 診斷應用
    • 抗體篩檢
    • 嵌合狀態監測
  • 調查申請

第 10 章 移植HLA型檢測市場：依最終使用者分類

  • 臨床實驗室/調查機構
  • 醫院及移植中心
  • 獨立參考實驗室

第11章 美洲HLA型檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太移植HLA型檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲、中東和非洲移植HLA型檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • GenDx 推出 NGS-Turbo：利用 Oxford Nanopore Technologies 的定序設備徹底改變高解析度HLA型檢測
    • Omixon 推出單重人類白血球抗原擴增試劑套件NanoTYPE MONO 和 MONOall RUO，與 Oxford Nanopore 的 MinION 平台相容。
    • JURA Bio 宣布與 Replay 產品公司 Syena 合作，推進癌症 T 細胞受體 NK 療法
    • Ossium Health 與 Be the Match 宣布合作，以提高骨髓移植的可近性和治療效率
    • BriaCell接受NCI津貼開發癌症平台
    • Tempus 宣布與 TScan Therapeutics 開展伴同性診斷合作
    • Metropolis Healthcare 推出下一代 HLA 器官移植檢測
    • CD Genomics Longseq 部門宣佈人類白血球抗原 (HLA) 分型服務
    • Garuda Therapeutics 獲得 6,200 萬美元 B 輪資金籌措，以推進現成的血液幹細胞技術平台
    • FDA 已授予HLA型檢測測試 De Novo 分類，用作轉移性或不可切除的葡萄膜黑色素瘤 T 細胞受體治療的診斷輔助。
    • Eurobioscientific 以 1.323 億美元收購 GenDx
    • Be The Match BioTherapies 與 Atara Biotherapeutics 延長多年夥伴關係協議

公司名單

  • Takara Bio Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • CapitalBio Technology Co., Ltd.
  • Pure MHC, LLC
  • Laboratory Corporation of America Holdings
  • TCR2 Therapeutics by Adaptimmune Therapeutics PLC
  • Bio-Techne Corporation
  • NeoGenomics Laboratories, Inc.
  • Oxford Nanopore Technologies PLC
  • Pure Protein, LLC
  • OraSure Technologies, Inc.
  • CareDx, Inc.
  • DiaSorin SpA
  • BAG Diagnostics GmbH
  • GenDx by Eurobio Scientific Group
  • TBG Diagnostics Ltd.
  • QIAGEN NV
  • HEALIOS KK
  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Illumina, Inc.
  • BGI Genomics Co.,Ltd.
  • Becton, Dickinson, and Company
  • Hologic, Inc.
  • Bio-Rad Laboratories, Inc.
  • Lonza Group Ltd.
  • STEMCELL Technologies Inc.
  • F. Hoffman-La Roche AG
  • CeGaT GmbH
  • Fujirebio, Inc. by HU Group Holdings, Inc.
  • Eurofins Scientific SE
  • Invectys Inc.
  • Creative Biolabs, Inc.
  • ImmunOs Therapeutics AG
  • Immucor, Inc. by Werfen, SA
  • Immatics NV
  • T-Cure Bioscience Inc.
  • Agilent Technologies, Inc.
  • Garuda Therapeutics
Product Code: MRR-3D2FD205B873

The HLA Typing for Transplant Market was valued at USD 998.31 million in 2023, expected to reach USD 1,086.39 million in 2024, and is projected to grow at a CAGR of 9.09%, to USD 1,836.58 million by 2030.

HLA typing for transplant is a crucial procedure in medical science that involves matching the human leukocyte antigens (HLA) of organ and tissue donors with those of recipients to ensure compatibility and reduce the risk of rejection. This process is vital in organ transplantation, including kidney, liver, heart, and bone marrow transplants, where precise matching can significantly influence the success rate and longevity of the transplant. The market for HLA typing is primarily driven by the rising incidence of organ failure and the increasing demand for organ transplants globally. Additionally, advancements in technology, particularly in molecular diagnostics, have enhanced the precision and efficiency of HLA typing, propelling its application in both hospitals and research laboratories. Key growth influencers include the rising awareness about organ donation, increasing government initiatives supporting transplantation activities, and the growing prevalence of chronic diseases leading to organ failure. However, challenges such as the high cost of HLA typing procedures, limited availability of organs, and ethical concerns surrounding organ transplantation act as restraints to market growth. Nevertheless, opportunities abound in the sector, particularly with the advancements in next-generation sequencing and the scope for personalized medicine. Companies poised to innovate in fields like automated and high-throughput HLA typing technologies may gain a competitive edge. Expansions in emerging markets, where healthcare infrastructure is rapidly improving, also present lucrative opportunities for market players. Despite these potential gains, stringent regulatory frameworks and the complexity of matching processes remain significant hurdles. Future research could focus on optimizing cost-effective techniques and improving the speed of HLA matching to enhance accessibility and efficiency. The market is characterized by a continuous demand for innovation and technological advancements, suggesting that companies investing in R&D and adopting digital healthcare solutions will likely lead in capturing market share.

KEY MARKET STATISTICS
Base Year [2023] USD 998.31 million
Estimated Year [2024] USD 1,086.39 million
Forecast Year [2030] USD 1,836.58 million
CAGR (%) 9.09%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving HLA Typing for Transplant Market

The HLA Typing for Transplant Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of bone marrow, organ, and blood transplant processes
    • Adoption of HLA typing in personalized medicine for reduced graft rejections
  • Market Restraints
    • Lack of reimbursement and inadequate insurance policies
  • Market Opportunities
    • Technological advancements in the field of transplant diagnostics and HLA-typing methods
    • Preference for immunosuppressive therapies to complement HLA typing
  • Market Challenges
    • Concerns regarding the inaccuracy of HLA typing

Porter's Five Forces: A Strategic Tool for Navigating the HLA Typing for Transplant Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the HLA Typing for Transplant Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the HLA Typing for Transplant Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the HLA Typing for Transplant Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the HLA Typing for Transplant Market

A detailed market share analysis in the HLA Typing for Transplant Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the HLA Typing for Transplant Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the HLA Typing for Transplant Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the HLA Typing for Transplant Market, highlighting leading vendors and their innovative profiles. These include Takara Bio Inc., Chugai Pharmaceutical Co., Ltd., CapitalBio Technology Co., Ltd., Pure MHC, LLC, Laboratory Corporation of America Holdings, TCR2 Therapeutics by Adaptimmune Therapeutics PLC, Bio-Techne Corporation, NeoGenomics Laboratories, Inc., Oxford Nanopore Technologies PLC, Pure Protein, LLC, OraSure Technologies, Inc., CareDx, Inc., DiaSorin S.p.A., BAG Diagnostics GmbH, GenDx by Eurobio Scientific Group, TBG Diagnostics Ltd., QIAGEN N.V., HEALIOS K.K., Thermo Fisher Scientific, Inc., Merck KGaA, Illumina, Inc., BGI Genomics Co.,Ltd., Becton, Dickinson, and Company, Hologic, Inc., Bio-Rad Laboratories, Inc., Lonza Group Ltd., STEMCELL Technologies Inc., F. Hoffman-La Roche AG, CeGaT GmbH, Fujirebio, Inc. by H.U. Group Holdings, Inc., Eurofins Scientific SE, Invectys Inc., Creative Biolabs, Inc., ImmunOs Therapeutics AG, Immucor, Inc. by Werfen, S.A., Immatics N.V., T-Cure Bioscience Inc., Agilent Technologies, Inc., and Garuda Therapeutics.

Market Segmentation & Coverage

This research report categorizes the HLA Typing for Transplant Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product & Service, market is studied across Instruments, Reagents & Consumables, and Software & Services.
  • Based on Technology, market is studied across Molecular Assay Technologies and Non-Molecular Assay Technologies. The Molecular Assay Technologies is further studied across PCR-Based Molecular Assays and Sequencing-Based Molecular Assays. The PCR-Based Molecular Assays is further studied across Real-Time PCR, Sequence-Specific Oligonucleotide-PCR, and Sequence-Specific Primer-PCR. The Sequencing-Based Molecular Assays is further studied across Next-Generation Sequencing and Sanger Sequencing.
  • Based on Transplant Type, market is studied across Organ Transplantation, Stem Cell Transplantation, and Tissue Transplantation.
  • Based on Application, market is studied across Diagnostic Applications and Research Applications. The Diagnostic Applications is further studied across Antibody Screening and Chimerism Monitoring.
  • Based on End-User, market is studied across Clinical Laboratories & Research Institution, Hospitals & Transplant Centers, and Independent Reference Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of bone marrow, organ, and blood transplant processes
      • 5.1.1.2. Adoption of HLA typing in personalized medicine for reduced graft rejections
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of reimbursement and inadequate insurance policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the field of transplant diagnostics and HLA-typing methods
      • 5.1.3.2. Preference for immunosuppressive therapies to complement HLA typing
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding the inaccuracy of HLA typing
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility
    • 5.2.2. Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow
    • 5.2.3. Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases
    • 5.2.4. Application: Use of HLA typing in diagnostic applications for organ transplantation
    • 5.2.5. End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. HLA Typing for Transplant Market, by Product & Service

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Consumables
  • 6.4. Software & Services

7. HLA Typing for Transplant Market, by Technology

  • 7.1. Introduction
  • 7.2. Molecular Assay Technologies
    • 7.2.1. PCR-Based Molecular Assays
      • 7.2.1.1. Real-Time PCR
      • 7.2.1.2. Sequence-Specific Oligonucleotide-PCR
      • 7.2.1.3. Sequence-Specific Primer-PCR
    • 7.2.2. Sequencing-Based Molecular Assays
      • 7.2.2.1. Next-Generation Sequencing
      • 7.2.2.2. Sanger Sequencing
  • 7.3. Non-Molecular Assay Technologies

8. HLA Typing for Transplant Market, by Transplant Type

  • 8.1. Introduction
  • 8.2. Organ Transplantation
  • 8.3. Stem Cell Transplantation
  • 8.4. Tissue Transplantation

9. HLA Typing for Transplant Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostic Applications
    • 9.2.1. Antibody Screening
    • 9.2.2. Chimerism Monitoring
  • 9.3. Research Applications

10. HLA Typing for Transplant Market, by End-User

  • 10.1. Introduction
  • 10.2. Clinical Laboratories & Research Institution
  • 10.3. Hospitals & Transplant Centers
  • 10.4. Independent Reference Laboratories

11. Americas HLA Typing for Transplant Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific HLA Typing for Transplant Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa HLA Typing for Transplant Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. GenDx launches NGS-Turbo: revolutionizing high-resolution HLA typing with Oxford Nanopore Technologies sequencing devices
    • 14.3.2. Omixon Launches NanoTYPE MONO and MONOall RUO, a Singleplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION Platform
    • 14.3.3. JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer
    • 14.3.4. Ossium Health and Be The Match Unveil Partnership to Increase Bone Marrow Transplant Accessibility and Treatment Efficiency
    • 14.3.5. BriaCell receives NCI grant for cancer platform development
    • 14.3.6. Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
    • 14.3.7. Metropolis Healthcare unveils NextGen HLA test for organ transplantation
    • 14.3.8. CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service
    • 14.3.9. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
    • 14.3.10. FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma
    • 14.3.11. Eurobio Scientific acquires GenDx for USD 132.3 million
    • 14.3.12. Be The Match BioTherapies, Atara Biotherapeutics Ink Multi-Year Partnership Extension

Companies Mentioned

  • 1. Takara Bio Inc.
  • 2. Chugai Pharmaceutical Co., Ltd.
  • 3. CapitalBio Technology Co., Ltd.
  • 4. Pure MHC, LLC
  • 5. Laboratory Corporation of America Holdings
  • 6. TCR2 Therapeutics by Adaptimmune Therapeutics PLC
  • 7. Bio-Techne Corporation
  • 8. NeoGenomics Laboratories, Inc.
  • 9. Oxford Nanopore Technologies PLC
  • 10. Pure Protein, LLC
  • 11. OraSure Technologies, Inc.
  • 12. CareDx, Inc.
  • 13. DiaSorin S.p.A.
  • 14. BAG Diagnostics GmbH
  • 15. GenDx by Eurobio Scientific Group
  • 16. TBG Diagnostics Ltd.
  • 17. QIAGEN N.V.
  • 18. HEALIOS K.K.
  • 19. Thermo Fisher Scientific, Inc.
  • 20. Merck KGaA
  • 21. Illumina, Inc.
  • 22. BGI Genomics Co.,Ltd.
  • 23. Becton, Dickinson, and Company
  • 24. Hologic, Inc.
  • 25. Bio-Rad Laboratories, Inc.
  • 26. Lonza Group Ltd.
  • 27. STEMCELL Technologies Inc.
  • 28. F. Hoffman-La Roche AG
  • 29. CeGaT GmbH
  • 30. Fujirebio, Inc. by H.U. Group Holdings, Inc.
  • 31. Eurofins Scientific SE
  • 32. Invectys Inc.
  • 33. Creative Biolabs, Inc.
  • 34. ImmunOs Therapeutics AG
  • 35. Immucor, Inc. by Werfen, S.A.
  • 36. Immatics N.V.
  • 37. T-Cure Bioscience Inc.
  • 38. Agilent Technologies, Inc.
  • 39. Garuda Therapeutics

LIST OF FIGURES

  • FIGURE 1. HLA TYPING FOR TRANSPLANT MARKET RESEARCH PROCESS
  • FIGURE 2. HLA TYPING FOR TRANSPLANT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. HLA TYPING FOR TRANSPLANT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. HLA TYPING FOR TRANSPLANT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HLA TYPING FOR TRANSPLANT MARKET DYNAMICS
  • TABLE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TISSUE TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ANTIBODY SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CHIMERISM MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CLINICAL LABORATORIES & RESEARCH INSTITUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 222. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 294. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 295. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 303. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 304. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR